News | September 04, 2024
Cupid targets Rs. 50 crore+ topline from B2C in FY 2024-25
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
The emergence of new infections in India is a growing concern
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Ajanta Pharma has reported total income of Rs. 1,171.39 crores during the period ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
